Altogen Biosystems Announced Its in Vivo Nanoparticle-Based Transfection Reagent is Effective in Brain-Targeted Drug Delivery and Capable of Overcoming Blood-Brain Barrier

Crossing Blood-Brain Barrier and In Vivo Delivery of Negatively Charged Biomolecules into Glioblastoma Enabled by Altogen's Nanoparticle In Vivo Transfection Reagent

Altogen Biosystems

Altogen Biosystems, leading manufacturer of in vivo transfection products, announced today that Altogen's nanoparticle-based in vivo Transfection reagent (product catalog #5031) was demonstrated to be effective for glioblastoma-targeted co-delivery of plasmid DNA (3.7kb) and chemically modified siRNA. This transfection reagent was used in over 30 research publications, demonstrating highly efficient delivery of cargo nucleic acids to the following tissues: lung, liver, pancreas, heart, kidney, and various tumor types. To enable effective delivery of small RNA and plasmid DNA into glioblastoma tissue, Altogen scientists developed and modified transfection protocol.

The nanoparticle-based in vivo transfection kit demonstrated high transfection efficiency into glioblastoma tissue in both spontaneous and chemically induced murine glioma syngeneic mouse models (GL26 and P560). The nanometer-sized particles are capable of crossing the capillary walls and are effectively endocytosed by glioblastoma cells. The results of the study (performed by Altogen Labs) demonstrated functional cargo delivery of small RNA and plasmid DNA biomolecules through the blood-brain barrier (a vital boundary between neural tissue and circulating blood) and high transfection reproducibility, thus representing a novel promising approach for medical applications such as gene and oligonucleotides therapy. In 2018, the company launched cGMP-grade Nanonarticle in vivo transfection reagent production required for clinical trials.

Altogen Biosystems offers over 120 optimized cell line transfection kits and 7 in vivo transfection reagents that are functionally tested in rodents to provide effective tissue-targeted delivery via various administration routes. Targeted delivery is highly effective not only in its usage but because it also minimizes the toxicity. In 2018, the company also launched a second generation transfection reagent for difficult to transfect cell lines and primary cell cultures (AltoFect), which is expected to be soon available as the cGMP grade transfection reagent.

About Altogen Biosystems:

Altogen Biosystems is a life sciences company, a leading developer and manufacturer of cell and tissue-targeted transfection products. Altogen scientists use polymer-based and combinatorial chemistry in combination with cell and molecular biology expertise to develop advanced transfection technologies, including in vitro and in vivo transfection reagents supplemented by optimized transfection protocols.

Altogen Biosystems
848 Rainbow Blvd #823
Las Vegas, NV, 89107 USA
Phone: (702) 349-6103
Fax: (702) 989-0841

Source: Altogen Biosystems